Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP
2
Receptor Antagonist for Treatment of Asthma"
ACS Med Chem Lett
.
2017 Sep 1;8(9):987.
doi: 10.1021/acsmedchemlett.7b00353.
eCollection 2017 Sep 14.
Authors
David A Sandham
1
,
Lucy Barker
1
,
Lyndon Brown
1
,
Zarin Brown
1
,
David Budd
1
,
Steven J Charlton
1
,
Devnandan Chatterjee
1
,
Brian Cox
1
,
Gerald Dubois
1
,
Nicholas Duggan
1
,
Edward Hall
1
,
Julia Hatto
1
,
Catherine Leblanc
1
,
Janet Maas
1
,
Jodie Manini
1
,
Rachael Profit
1
,
Darren Riddy
1
,
Catherine Ritchie
1
,
Bindi Sohal
1
,
Duncan Shaw
1
,
Rowan Stringer
1
,
David A Sykes
1
,
Matthew Thomas
1
,
Katharine L Turner
1
,
Simon J Watson
1
,
Ryan West
1
,
Elisabeth Willard
1
,
Gareth Williams
1
,
Jennifer Willis
1
Affiliation
1
Novartis Institutes for Biomedical Research, Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom.
PMID:
28947949
PMCID:
PMC5601380
DOI:
10.1021/acsmedchemlett.7b00353
Abstract
[This corrects the article DOI: 10.1021/acsmedchemlett.7b00157.].
Publication types
Published Erratum